5-Year imatinib after GIST surgery for high-risk patients
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study looks at taking imatinib (a targeted anti-cancer pill) for 5 years after your GIST tumor has been fully removed. It is meant to lower the chance that GIST comes back in people considered “high risk.”
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 20 or older and can give written informed consent
- Your tumor is confirmed to be GIST, and tests show it has certain markers (KIT or PDGFRα, or specific protein types)
- Your GIST was completely removed by surgery (R0 resection) within the last 12 weeks
- You are currently on adjuvant imatinib after surgery, and your GIST is “high risk” based on specific features
- Your general strength is good (ECOG 0 to 2) and your blood, liver, and kidney tests are adequate
- You can’t have certain conditions (like pregnancy, major recent heart/stroke events, uncontrolled infection, or HIV). You also must not have the PDGFRα D842V mutation
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how well temozolomide works and how safe it is for people with GIST (a type of stomach/intestine tumor) that is SDH-deficient and has no KIT or PDGFRα mutations. It may help by targeting tumor DNA repair weakness seen in this SDH-deficient subtype.
This Phase 2 trial studies how to adjust and monitor imatinib (a targeted cancer medicine) based on drug levels in the blood. It may help people with GIST that has certain KIT or PDGFRA mutations but not the PDGFRA D842V type.
This trial tests whether combining two oral medications, imatinib and fampridine, before surgery can shrink GIST tumors that have a specific KIT gene mutation. The goal is to improve surgical outcomes and potentially reduce the risk of the tumor coming back.
This trial studies whether apatinib works better than the usual second-line targeted tablet for advanced gastrointestinal stromal tumor (GIST) after imatinib (or avatinib) no longer works. It may help people whose cancer has grown despite treatment or who couldn’t tolerate it.
This study uses a blood test (ctDNA) to look for specific tumor DNA changes, then guides treatment with sunitinib or regorafenib in people with GIST that has spread or cannot be removed by surgery. It aims to see whether this ctDNA-guided approach improves outcomes compared with standard decision-making.
This trial tests a drug called lenvatinib for people with advanced GIST that has not responded to three previous treatments. It may offer a new option if standard therapies have stopped working or caused severe side effects.
Hear when a new Gastrointestinal Stromal Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.